Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports
Related Experiment Video
Updated: Aug 19, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
1Infectious Diseases Clinic, University of Foggia, Via L. Pinto 1, I-71100 Foggia, Italy. gaescot@tin.it
Abstract:
Acute hepatitis C often progresses to chronic infection (70%). In this clinical study, we evaluated if early treatment with peginterferon alfa-2b can prevent acute hepatitis C from developing into a chronic disease. Six patients with acute hepatitis C, based on a well-documented hepatitis C virus (HCV) seroconversion with high alanine aminotransferase (ALT) levels (> 10 x ULN) and persistent HCV RNA titers after 3 months from disease onset, were consecutively treated with peginterferon alfa-2b at 1.5 microg/kg/weekly/sc for 24 weeks. The viral load was quantified by PCR assay. Response was defined as undetectable HCV RNA and normal ALT levels at the end of therapy and after a 6-month follow-up. All patients completed therapy; at the end of therapy, 5/6 patients (83%) responded and no relapses were observed during follow-up. No correlation was found between treatment response and pretreatment viral load, viral genotype, and interval between acute infection diagnosis and start of therapy.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acute Pancreatitis II: Clinical Manifestations and Management
